Miami Dade County ASsessment of Phylogenetics to Improve Resource Equity: MD ASPIRE NIMH R01MH132151Jul 1, 2022 - Jun 30, 2027 Role: MPI Description: To date, the use of HIV molecular surveillance has not been linked to a reduction in HIV incidence. The proposed project will perform secondary analyses of coded and de-identified public health HIV surveillance data from the Los Angeles County (LAC) Health Department. The study team will engage key stakeholder populations and use regional estimates of HIV transmission and HIV program data to project the impact of alternative strategies for the optimal allocation of resources to LAC HIV prevention programs relevant to EHE targets. |
Simulation Modeling to Support the Public Health Response to the Opioid Crisis in North America NIH R13DA052198Jun 1, 2021 - May 31, 2024 Role: Co-Principal Investigator |
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism NIH/NIDA R01DA049644Apr 1, 2020 - Jan 31, 2025 Role: Co-Investigator |
Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling NIH R01AI147490Aug 7, 2019 - Jul 31, 2023 Role: Principal Investigator |
Integrating HCV services into HIV programs for PWID in India NIH R01AI145555Jul 8, 2019 - Jun 30, 2024 Role: Co-Investigator |
University of California, San Diego, Center for AIDS Research NIH 5 P30 AI036214Apr 1, 2018 - Mar 31, 2023 Role: Co-Director, Biostatistics and Modeling Core |
Modeling Structural HIV Determinants in Substance Users and related populations NIH R01DA037773Apr 1, 2015 - Dec 31, 2018 Role: Principal Investigator |
The Impact of HCV Treatment in HIV/HCV coinfected and HCV monoinfected Incarcerated Persons on HCV Elimination NIH R01DA013806Sep 20, 2000 - Aug 31, 2025 Role: Co-Investigator |
Modeling opioid overdose and prevention in Australia Australian NHMRC Dec 31, 2023 Role: Co-I |
Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs (EPIToPe). UK National Institute for Health Research Feb 1, 2023 Role: Co-investigator |
HCV elimination among men who have sex with men in Germany Gilead Jun 1, 2022 Role: Co-investigator |
Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego Gilead Jan 1, 2021 Role: Co-PI |
Modeling HCV elimination among HIV-infected men who have sex with men and people who inject drugs Gilead Dec 31, 2020 Role: Principal Investigator |
Testing and comparing study designs for evaluating HCV treatment as prevention (TasP) impact in a real world setting Merck Dec 1, 2020 Role: Principal Investigator |
Cost-effectiveness of HCV testing and treatment in pregnant women Gilead Apr 30, 2020 Role: Principal Investigator |
Surveillance and Treatment of Prisoners with hepatitis C (STOP-C) Australian NHMRC Dec 31, 2019 Role: Co-Investigator Description: To test HCV treatment as prevention among prisoners in New South Wales, Australia. Overseeing modeling to inform trial design, implementation and evaluation. |